Despite its potential, CRISPR has limitations. Off-target effects, where the CRISPR system edits unintended parts of the genome, can lead to unexpected consequences. Additionally, delivering the CRISPR components to the right cells in the body remains a challenge. There is also the issue of ensuring that the edited genes are expressed correctly and function as intended. These limitations need to be addressed to fully harness the power of CRISPR in epidemiology.
